We have recently reported that serum TSP-2 is a novel biomarker for identifying NASH, advanced fibrosis, and HCC occurrence among nonalcoholic fatty liver disease (NAFLD) patients [11]. Here, THBS2 is linked to metabolic dysfunction-associated steatohepatitis.